Biocept Inc (BIOC)

1.43
0.02 1.38
NASDAQ : Health Care
Prev Close 1.45
Open 1.46
Day Low/High 1.40 / 1.46
52 Wk Low/High 0.56 / 2.76
Volume 240.16K
Avg Volume 575.60K
Exchange NASDAQ
Shares Outstanding 26.60M
Market Cap 38.57M
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biocept Awarded U.S. Patent With Broad Claims For Antibody Capture Of Targets Of Interest On Any Solid Surface Including CTCs And Other Materials Shed By Solid Tumors Into Blood

Company's intellectual property portfolio now features 20 issued patents protecting its proprietary liquid biopsy platform technology

Biocept's Target Selector Platform Featured In Three Clinical Abstracts At The 2017 American Society Of Clinical Oncology Annual Meeting Where Company Plans To Launch New Marketing Campaign

Abstracts feature clinical results demonstrating the high sensitivity of Biocept's Target Selector™ platform and the ability to identify mutations that may be missed by tissue biopsy

The Addario Lung Cancer Medical Institute And Biocept Announce Collaboration And Initiation Of Landmark ALCMI-009 Liquid Biopsy Clinical Trial In Lung Cancer

Large prospective multi-center clinical trial designed to evaluate the impact of cancer biomarker detection and serial monitoring using liquid biopsy to improve the outcomes of patients with lung cancer

Biocept Awarded Additional Patent In Japan Expanding Intellectual Property Estate To 19 Issued Patents Protecting Its Target Selector™ Liquid Biopsy Platform

New patent provides broad coverage for the use of antibodies to capture targets of interest, including circulating tumor cells (CTCs) and other materials shed by solid tumors into the blood stream

Biocept Announces Collaboration With The OHSU Knight Cancer Institute To Increase Clinical Adoption Of Liquid Biopsy Testing And To Co-Develop Additional Assay Platform Capabilities

NCI-designated cancer institute with leading molecular pathology lab obtains rights to utilize and commercially offer Biocept's Target Selector™ liquid biopsy services throughout the state of Oregon

Biocept Announces Revised Presentation Time At The 27th Annual Oppenheimer Healthcare Conference

Company presentation set for March 22 at 1:00 p.m. ET

Biocept And Catalyst Pharmaceuticals Collaborate To Provide Liquid Biopsy Testing For Small Cell Lung Cancer To Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Catalyst Pharmaceuticals to make Biocept's Target Selector™ test available to LEMS patients in Phase III Firdapse® trial to screen for cancer every six months for up to two years, at no cost to patients

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Explode Up Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Biocept's CEO Issues Letter To Stockholders

Highlights key accomplishments and outlines value drivers for 2017

Biocept Awarded Patent In Australia For The Use Of Antibodies In Microchannels To Capture Circulating Tumor Cells And Other Rare Cells

Biocept Awarded Patent In Australia For The Use Of Antibodies In Microchannels To Capture Circulating Tumor Cells And Other Rare Cells

Biocept further expands its global patent estate for capturing and detecting cells that are in very low abundance and that can provide important molecular information from biological fluids

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Stocks with insider trader activity include BA, WLL and BIOC

8 Stocks Under $10 to Trade for Big Gains

8 Stocks Under $10 to Trade for Big Gains

These under-$10 stocks are making big moves higher. Here's how to trade them from here.

Biocept (BIOC) Stock Popping on Blue Cross Blue Shield Partnership

Biocept (BIOC) Stock Popping on Blue Cross Blue Shield Partnership

Biocept (BIOC) stock is surging in mid-morning trading on Tuesday after the company announced an agreement with Blue Cross Blue Shield of Illinois.

Rosetta Genomics And Biocept Advance Collaboration To Proof-of-Concept Studies Aimed At MicroRNA Profiling Of Circulating Tumor Cells To Enhance Lung Cancer Diagnosis

Rosetta Genomics And Biocept Advance Collaboration To Proof-of-Concept Studies Aimed At MicroRNA Profiling Of Circulating Tumor Cells To Enhance Lung Cancer Diagnosis

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, and Biocept, Inc.

Lung Cancer Study Demonstrates Extremely High Sensitivity Of Biocept's Blood-Based Liquid Biopsy Platform In Detecting EGFR Mutation In Plasma With 93% Concordance With Tissue Biopsy

Lung Cancer Study Demonstrates Extremely High Sensitivity Of Biocept's Blood-Based Liquid Biopsy Platform In Detecting EGFR Mutation In Plasma With 93% Concordance With Tissue Biopsy

Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of cancer, today announced that findings...

Biocept To Present At 2015 Aegis Growth Conference

Biocept To Present At 2015 Aegis Growth Conference

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael Nall is scheduled to...

Biocept Announces Participation In MultiPlan's Networks

Biocept Announces Participation In MultiPlan's Networks

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that it has entered into an agreement with MultiPlan,...

Biocept Secures Agreements With Preferred Provider Organizations Stratose And Galaxy Health Network For Its Proprietary Blood-Based Oncology Diagnostic Assays

Biocept Secures Agreements With Preferred Provider Organizations Stratose And Galaxy Health Network For Its Proprietary Blood-Based Oncology Diagnostic Assays

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing assays for liquid biopsies to improve the detection and treatment of cancer, announces additional agreements with preferred...

Biocept Expands U.S. Microchannel Patent Protection

Biocept Expands U.S. Microchannel Patent Protection

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces the allowance of U.